How the NOPAIN Act could support broader reimbursement momentum for EXPAREL

Pacira BioSciences (NASDAQ: PCRX) unveiled new health economics findings from a real-world outpatient shoulder arthroplasty study suggesting that EXPAREL use was associated with lower opioid exposure, fewer opioid-related complications, and reduced 90-day healthcare costs among Medicare Advantage patients. The data, presented at the 2026 ISPOR annual meeting, come as the NOPAIN Act begins influencing reimbursement discussions around non-opioid pain management strategies in outpatient surgical care.

Why the NOPAIN Act could fundamentally alter non-opioid pain management economics in outpatient orthopedic surgery

The broader importance of Pacira BioSciences’ latest study lies less in the clinical novelty of EXPAREL and more in how the company is positioning itself within a changing reimbursement environment. For years, non-opioid pain management products faced a recurring commercial obstacle because hospitals and ambulatory surgery centers often absorbed the incremental cost of premium analgesic therapies without direct reimbursement support tied specifically to opioid-sparing approaches.

The NOPAIN Act is beginning to alter that equation. The legislation, designed to improve Medicare reimbursement access for qualifying non-opioid pain therapies in outpatient settings, reflects growing federal concern surrounding opioid exposure after surgery. Regulatory observers note that the policy effectively shifts the healthcare conversation away from whether opioid reduction matters and toward how providers can operationalize opioid-sparing protocols without worsening financial pressure.

That distinction is critical for products such as EXPAREL because the commercial challenge surrounding non-opioid analgesics has historically centered as much on economics as on clinical performance. Hospitals may acknowledge the benefits of reducing opioid exposure, but pharmacy budgets and reimbursement constraints often limit broad adoption of premium therapies unless measurable financial offsets become visible.

Pacira BioSciences appears to recognize that reality clearly. The company’s latest presentation focused heavily on healthcare utilization and downstream cost reduction rather than relying solely on pain-control outcomes. Industry analysts suggest this reflects a strategic pivot toward value-based healthcare positioning, where economic efficiency increasingly carries equal weight with clinical efficacy.

How Pacira BioSciences is attempting to reposition EXPAREL as a value-based care solution rather than a premium analgesic product

Orthopedic surgery is emerging as one of the most important battlegrounds in that reimbursement transition. Outpatient joint reconstruction procedures continue growing as aging demographics increase procedural demand while health systems simultaneously push for lower-cost care settings. Providers operating within ambulatory environments face intense pressure to shorten recovery timelines, reduce complication rates, and avoid costly readmissions or opioid-related utilization. As a result, non-opioid therapies capable of supporting operational efficiency may become increasingly attractive under reimbursement systems rewarding episode-of-care optimization rather than procedural volume alone.

Pacira BioSciences has spent years defending EXPAREL against criticism centered on acquisition cost and inconsistent institutional adoption patterns. While many clinicians accept that liposomal bupivacaine formulations can contribute to opioid reduction strategies, the unresolved commercial debate has focused on whether the clinical advantages consistently justify the pricing premium compared with generic local anesthetics and evolving multimodal care protocols.

The latest ISPOR data appears designed to strengthen the economic argument directly. By emphasizing lower healthcare costs over a 90-day postoperative period, Pacira BioSciences is attempting to reposition EXPAREL as part of a broader value-based care framework rather than simply a branded pain management product.

Industry observers note that postoperative pain management no longer functions as an isolated clinical decision. Hospitals are increasingly measuring total episode-of-care economics, including complication management, opioid-related adverse events, emergency department utilization, recovery disruptions, and rehabilitation timelines.

The focus on outpatient total shoulder arthroplasty is strategically significant. Shoulder replacement procedures often involve substantial postoperative pain management requirements while also serving as an expanding outpatient orthopedic category. Providers are increasingly seeking perioperative strategies capable of supporting same-day discharge pathways and smoother recovery experiences without increasing opioid dependency risk.

Why retrospective claims-based orthopedic pain management studies may still fall short of payer and clinician evidence standards

Despite the favorable data, important limitations remain attached to the study design itself. The analysis was retrospective and observational, meaning it can identify associations but cannot definitively prove causation. Claims-based datasets may also be influenced by institutional protocol differences, surgeon preferences, patient demographics, and perioperative management strategies unrelated to EXPAREL use directly. That limitation matters because healthcare payers and institutional formulary committees increasingly demand high-quality comparative evidence before expanding reimbursement or utilization support for premium therapies.

Clinicians tracking orthopedic pain management trends note that multimodal analgesia protocols have evolved substantially during the past decade. Hospitals now routinely combine nerve blocks, regional anesthesia techniques, nonsteroidal anti-inflammatory drugs, generic anesthetics, and enhanced recovery pathways to reduce opioid exposure. As a result, EXPAREL is no longer competing primarily against traditional opioid-heavy recovery models.

Instead, Pacira BioSciences is competing against increasingly sophisticated and often lower-cost multimodal pain management ecosystems. Some orthopedic specialists continue debating whether liposomal bupivacaine formulations consistently deliver superior real-world outcomes compared with lower-cost alternatives integrated into optimized enhanced recovery programs.

Payers are also likely to scrutinize whether cost reductions observed in retrospective analyses remain durable and reproducible across diverse provider networks. Economic benefits demonstrated within one dataset may not automatically translate across all outpatient orthopedic settings.

How outpatient surgery migration trends could create both opportunity and pricing pressure for EXPAREL adoption

The continued migration of orthopedic procedures into outpatient settings creates both opportunity and risk for Pacira BioSciences. Outpatient surgery economics favor interventions capable of reducing recovery disruptions, minimizing postoperative complications, and supporting discharge efficiency. Providers operating ambulatory centers typically have limited tolerance for extended recovery complications or avoidable readmissions because operational margins depend heavily on procedural throughput and predictable outcomes.

Non-opioid therapies aligned with smoother outpatient recovery pathways may therefore gain increasing relevance. At the same time, outpatient surgery centers are often highly sensitive to supply-chain and pharmacy costs. Unlike large inpatient hospital systems, many ambulatory providers operate with leaner financial structures and tighter reimbursement margins. That creates ongoing pricing pressure for manufacturers selling premium perioperative products.

Industry analysts note that the long-term commercial trajectory for EXPAREL may depend on whether Pacira BioSciences can continue proving that the product generates measurable financial offsets rather than merely clinical differentiation. If opioid-related adverse event reductions and lower downstream utilization consistently translate into improved procedural economics, broader adoption could become easier to justify. However, if competing multimodal protocols continue improving at lower cost, the pricing debate surrounding liposomal bupivacaine formulations is unlikely to disappear entirely.

What investors, healthcare systems, and regulators will likely watch next for Pacira BioSciences and EXPAREL

The next phase of scrutiny surrounding EXPAREL will likely center on whether Pacira BioSciences can convert reimbursement momentum into sustained procedural growth and broader institutional adoption. Healthcare systems will likely monitor whether opioid-sparing reimbursement frameworks under the NOPAIN Act materially improve perioperative economics for non-opioid therapies. Investors, meanwhile, will watch whether Pacira BioSciences can defend pricing power while maintaining relevance in an increasingly competitive pain management landscape.

Clinicians are also likely to focus on whether additional prospective studies validate the economic findings highlighted in the current retrospective analysis. Stronger comparative evidence examining recovery efficiency, complication reduction, opioid exposure, and total episode-of-care costs could carry greater influence in payer negotiations than observational datasets alone.

The broader significance of Pacira BioSciences’ latest data may lie in how it reflects changing healthcare priorities rather than in the individual study itself. Pain management therapies are increasingly being evaluated not only on pharmacologic performance, but also on their ability to support value-based care models, reduce downstream healthcare utilization, and align with evolving reimbursement incentives focused on operational efficiency and opioid stewardship.

Key takeaways on what this development means for Pacira BioSciences, competitors, and the outpatient orthopedic market

• Pacira BioSciences is increasingly positioning EXPAREL as a value-based healthcare solution rather than solely a premium analgesic therapy.
• The NOPAIN Act could improve reimbursement visibility for non-opioid pain management products in Medicare outpatient settings.
• Outpatient orthopedic surgery remains a strategically important growth category for opioid-sparing perioperative care models.
• Hospitals and ambulatory surgery centers are placing greater emphasis on downstream recovery economics rather than isolated pain-control metrics.
• Retrospective claims-based studies may influence payer discussions but still face evidentiary limitations compared with prospective randomized trials.
• Competitive pressure from lower-cost multimodal analgesia protocols remains a long-term commercial challenge for EXPAREL.
• Investors will likely monitor whether reimbursement momentum translates into durable procedural growth and pricing stability.
• The broader pain management market is shifting toward operational efficiency and episode-of-care economics rather than standalone therapeutic differentiation.